A new chemotherapy combination comprising gemcitabine and cisplatin shows promise in endometrial cancer treatment, American researchers have reported.
The study, conducted by scientists from The University of Texas M. D. Anderson Cancer Center, showed that the combination produced a response rate in 50 percent of patients.
Although early-stage endometrial cancer typically responds well to standard therapies, low survival rates for advanced or recurrent disease ...
A new chemotherapy combination comprising gemcitabine and cisplatin shows promise in endometrial cancer treatment, American researchers have reported.
The study, conducted by scientists from The University of Texas M. D. Anderson Cancer Center, showed that the combination produced a response rate in 50 percent of patients.
Although early-stage endometrial cancer typically responds well to standard therapies, low survival rates for advanced or recurrent disease ...